Association of CYP2B6 Single-Nucleotide Polymorphisms Altering Efavirenz Metabolism With Hepatitis C Virus (HCV) Treatment Relapse Among Human Immunodeficiency Virus/HCV-Coinfected African Americans Receiving Ledipasvir/Sofosbuvir in the ION-4 Trial.
Journal Article (Clinical Trial, Phase III;Journal Article;Multicenter Study)
In the ION-4 trial, hepatitis C virus relapse was rare, occurring only in African American patients, 80% receiving efavirenz for human immunodeficiency virus infection. We observed no indication that CYP2B6 polymorphisms associated with increased plasma efavirenz exposure explained the relapses.
Full Text
Duke Authors
Cited Authors
- Kleinstein, SE; Shea, PR; Stamm, LM; Sulkowski, M; Goldstein, DB; Naggie, S
Published Date
- June 1, 2018
Published In
- Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
Volume / Issue
- 66 / 12
Start / End Page
- 1953 - 1956
PubMed ID
- 29522085
Electronic International Standard Serial Number (EISSN)
- 1537-6591
Digital Object Identifier (DOI)
- 10.1093/cid/cix1051
Language
- eng
Conference Location
- United States